Indeed, despite nowadays the first line standard protocol for adult AML treatment still forecasts an induction-consolidation regimen with DNA damaging agents (e.g., DNA topoisomerase inhibitors), lately patients are also successfully treated with FLT3 [39] and Isocitrate Dehydrogenase 1/2 (IDH1/IDH2) inhibitors [40]. Here, IDH1 is linked to acute myeloid leukemia.